News Headlines
-
Almac Group Expands Commercial Manufacturing And Packaging As Well As Peptide Production Capacity
3/6/2024
The Almac Group has today announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland meeting client demand in commercial manufacturing and packaging as well as peptide production.
-
CordenPharma Expands Early Clinical Peptide Manufacturing To Launch IND-Targeted Peptide API To Injectable Drug Product Integrated Offer
3/6/2024
After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary performance delivered by their expert team, CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers.
-
Coriolis Pharma Adds Analytical Ultracentrifugation For Release Testing To Its Service Offerings
3/6/2024
Coriolis Pharma, a globally operating service provider for drug product development, analytics and manufacturing support, proudly announces the introduction of Analytical Ultracentrifugation (AUC) under GMP.
-
Rentschler Biopharma Will Be Involved In Almost 25% Of The New Biopharmaceuticals Approved By The FDA In 2023
3/6/2024
55 new drugs were newly approved by the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) in 2023, including 17 biopharmaceutical drugs.
-
Elizabeth Hickman To Succeed Tim Scott As AustinPx CEO
3/5/2024
AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol™ Technology, and a contract development and manufacturing organization (CDMO), today announced that Elizabeth Hickman, chief business officer, will succeed Tim Scott in January 2025 as president and CEO of AustinPx. Scott has led the company’s new direction as a CDMO since 2022, successfully positioning the company’s leadership as an oral drug delivery dosage form development CDMO. Scott will stay on as executive chair following the transition and Hickman will be named to the Board of Directors.
-
Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities With $45M Equity Investment From NewVale Capital And Telegraph Hill Partners
3/5/2024
Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45M financing to support its new drug product fill / finish expansion.
-
Epsilogen And Lonza Announce Successful Large-Scale GMP Manufacturing Of MOv18, An IgE Antibody Targeting Ovarian Cancer
3/5/2024
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate.
-
Polyplus Expands GMP Offer With Protein Production And Adds GMP Capacity In Belgium
3/5/2024
Xpress Biologics, a good manufacturing practice (GMP) certification for recombinant protein production, and renewed the January 2023 GMP certification for DNA production at the facility located in Belgium.
-
Adare Pharma Solutions To Expand Packaging & Warehousing Capabilities In Europe
3/5/2024
Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced that work has begun to add packaging capabilities and further warehousing capacity at its Pessano facility in Milan, Italy.
-
BridgeBio Pharma And Bayer Announce European Licensing Agreement For Acoramidis In ATTR-CM
3/4/2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe. In exchange, BridgeBio will receive up to $310 million USD comprising of upfront and near-term milestone payments, as well as additional undisclosed sales milestones.